TB-500 has been shown to promote cell migration, angiogenesis, cytoskeletal reorganization, and anti-inflammatory signaling in preclinical models 1,2
NCT03600480), in which 96 participants with a BMI of 27.039.9 kg/m were randomised 3:1 to once-weekly subcutaneous cagrilintide (0.16, 0.30, 0.60, 1.2, 2.4 or 4.5 mg) or matched placebo, each in combination with once-weekly semaglutide 2.4 mg , across six sequential overlapping cohorts
Healing Acceleration: The peptide stimulates the production of collagen, a protein essential for tissue repair
A Note on Informed Consent and Patient Education At BlueWater, we believe the most important conversation we can have with Jacksonville and Ponte Vedra Beach patients interested in BPC-157 is an honest one